Long-term therapy with 1alpha-hydroxyvitamin D3 in children with 'pseudo-deficiency' rickets. 1977

S Balsan, and M Garabedian, and V Courtecuisse, and J Guéris, and J P Dommergues, and L Creignou, and M J le Denuff, and J Rivron

This investigation confirms that 1alpha-hydroxyvitamin D3 (1alpha-OHD3) is a potent drug for the treatment of patients with pseudo-deficiency rickets (Balsan et al., 1975a; Reade et al., 1975; Prader et al., 1976). 1alpha-OHD3 corrects their intestinal malabsorption of calcium and phosphorus, normalizes their serum calcium and phosphate concentrations and promotes healing of skeletal lesions. This study also shows differences in the needs for 1alpha-OHD3 of children with PDR. Three factors appear to be of importance: familial sensitivity, severity of chronic secondary hyperparathyroidism, and periods of increased growth velocity. Tolerance to long-term 1alpha-OHD3 therapy, at doses varying from 0.5 to 2 microgram/d is excellent. Surveillance of patients should include regular measurements of 24 h urinary excretion of calcium, since hypercalciuria is the first signal of overdosage.

UI MeSH Term Description Entries
D007015 Hypophosphatemia, Familial An inherited condition of abnormally low serum levels of PHOSPHATES (below 1 mg/liter) which can occur in a number of genetic diseases with defective reabsorption of inorganic phosphorus by the PROXIMAL RENAL TUBULES. This leads to phosphaturia, HYPOPHOSPHATEMIA, and disturbances of cellular and organ functions such as those in X-LINKED HYPOPHOSPHATEMIC RICKETS; OSTEOMALACIA; and FANCONI SYNDROME. Diabetes, Phosphate,Familial Hypophosphatemia,Hyperphosphaturia,Phosphate Diabetes,Phosphaturia,Familial Hypophosphatemias,Hypophosphatemias, Familial
D008297 Male Males
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006887 Hydroxycholecalciferols Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3. Hydroxyvitamins D,Hydroxycholecalciferol
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

S Balsan, and M Garabedian, and V Courtecuisse, and J Guéris, and J P Dommergues, and L Creignou, and M J le Denuff, and J Rivron
March 1998, The New England journal of medicine,
S Balsan, and M Garabedian, and V Courtecuisse, and J Guéris, and J P Dommergues, and L Creignou, and M J le Denuff, and J Rivron
December 1977, Clinical endocrinology,
S Balsan, and M Garabedian, and V Courtecuisse, and J Guéris, and J P Dommergues, and L Creignou, and M J le Denuff, and J Rivron
December 1977, Clinical endocrinology,
S Balsan, and M Garabedian, and V Courtecuisse, and J Guéris, and J P Dommergues, and L Creignou, and M J le Denuff, and J Rivron
December 1977, Clinical endocrinology,
S Balsan, and M Garabedian, and V Courtecuisse, and J Guéris, and J P Dommergues, and L Creignou, and M J le Denuff, and J Rivron
December 1977, Clinical endocrinology,
S Balsan, and M Garabedian, and V Courtecuisse, and J Guéris, and J P Dommergues, and L Creignou, and M J le Denuff, and J Rivron
December 1977, Clinical endocrinology,
S Balsan, and M Garabedian, and V Courtecuisse, and J Guéris, and J P Dommergues, and L Creignou, and M J le Denuff, and J Rivron
July 1981, The Journal of pediatrics,
S Balsan, and M Garabedian, and V Courtecuisse, and J Guéris, and J P Dommergues, and L Creignou, and M J le Denuff, and J Rivron
December 1977, Clinical endocrinology,
S Balsan, and M Garabedian, and V Courtecuisse, and J Guéris, and J P Dommergues, and L Creignou, and M J le Denuff, and J Rivron
December 1977, Clinical endocrinology,
S Balsan, and M Garabedian, and V Courtecuisse, and J Guéris, and J P Dommergues, and L Creignou, and M J le Denuff, and J Rivron
November 1999, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!